Abstracts tagged "pathogenesis and psoriatic arthritis"

Abstract Number: 2787 • 2018 ACR/ARHP Annual Meeting
−21 HLA-Class I Dimorphism Differentiates Psoriatic Arthritis (PsA) from Psoriasis without Psoriatic Arthritis (PsC)
Vinod Chandran¹, Quan Li², Rohan Machhar², Fatima Abji¹, Justine Y. Ye¹, Rajan Nair³, Philip Stuart³, Katerina Oikonomopoulou², James T. Elder⁴, Dafna D Gladman² and Proton Rahman⁵, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Michigan, Ann Arbor, MI, ⁴University of Michigan Medical School, Ann Arbor, MI, ⁵Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada
Background/Purpose: The association between human leukocyte antigen (HLA) class I alleles and psoriatic disease indicates a potential role for the innate immune system in disease…
Abstract Number: 2068 • 2018 ACR/ARHP Annual Meeting
The Role of Extracellular Matrix Metalloproteinase Inducer Emmprin in the Pathogenesis of Psoriatic Arthritis
Devy Zisman^1,2, Mirna Saphieh², Joy Feld³, Amir Haddad³, Muna Elias³, Alina Kaganovitch³, Idit Lavi⁴ and Michal Amit Rahat^2,5, ¹Technion, Rheumatology Unit Carmel Medical Center, Haifa, Israel, ²The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel, ³Rheumatology Unit Carmel Medical Center, Haifa, Israel, ⁴Epidemiology Unit Carmel Medical Center, Haifa, Israel, ⁵Immunotherapy Laboratory Carmel Medical Center, Haifa, Israel
Background/Purpose: Angiogenesis is an essential component in the pathogenesis of psoriatic arthritis (PsA). Extracellular matrix metalloproteinase inducer (EMMPRIN) is a multifunctional protein that can enhance…
Abstract Number: 649 • 2017 ACR/ARHP Annual Meeting
Role of Eicosanoids As Biomarkers in Psoriatic Arthritis
Roxana Coras^1,2, Arthur Kavanaugh¹, Doquyen H. Huynh¹, Aladdin Shadyab³, Sara Marsal⁴, Oswald Quehenberger⁵ and Monica Guma¹, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Medicine, Autonomous University of Barcelona, Barcelona, Spain, ³Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, ⁴Rheumatology Research Unit, Vall d'Hebron Hospital, Barcelona, Spain, ⁵Pharmacology, Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory disease affecting the joints and connective tissue and is associated with psoriasis of the skin and nails. There…
Abstract Number: 658 • 2017 ACR/ARHP Annual Meeting
Functionally Active MAIT Cells in Psoriatic Arthritis: A New Member of the IL-23/IL-17 Cytokine Network
Siba P. Raychaudhuri¹ and Smriti K. Raychaudhuri², ¹Rheumatology Section, Sacramento Veterans Affairs Medical Center, Sacramento, CA, ²Rheumatology/Immunology, VA Sacramento Medical Center, Davis, CA
Background/Purpose: The mucosal-associated invariant T (MAIT) cells recently have been implicated in autoimmune diseases. Murine model experiments also suggest that MAIT cells are capable…
Abstract Number: 982 • 2015 ACR/ARHP Annual Meeting
CD4+CD146+ T Cells: The Primed IL-17 Secreting Cells in the Pathogenesis of Psoriatic Arthritis
Siba Raychaudhuri¹ and Smriti K. Raychaudhuri², ¹Med/Rheumatology, Univ California Davis/VA Sacramento, Davis, CA, ²Rheumatology/Immunology, VA Sacramento Medical Center, Davis, CA
Background/Purpose: CD146, also called melanoma cell adhesion molecule (MCAM), is a cell surface adhesion molecule. A small minority of the T cell population also express…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].